Informationen auf deutsch

in collaboration with the University of Vienna and various oncologic departments

• pharmacokinetics and metabolism of erlotinib after multiple doses (ongoing)
• pharmacokinetics and metabolic activation of irinotecan after intra-arterial infusion for treatment of advanced colorectal cancer. published
• pharmacokinetics and metabolic activation of capecitabine after different dose schedules(ongoing)
• epimerization of docetaxel into 7'-epidocetaxel during conventional chemotherapy of colorectal cancer with Taxotere® (finshed)
• clinical pharmacokinetics of irinotecan when combined with biweekly cetuximab in the treatment of colorectal cancer (published)
• formation of reactive oxygen species (ROS) during chemotherapy of solid tumours

• Czejka M, Greil R, Ulsperger E, Schnait H, Kienesberger K, Brumnik T,Schierholz J, Farkouh A:
  Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving conventional chemotherapy with taxotere®. Int J of Clinical Pharmacology and Therapeutics. July 2010 in press
• Farkouh A, Schueller J, Scheithauer W, Czejka M:
  Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) during two different capecitabine / oxaliplatin dosage regimens. Int J of Clinical Pharmacology and Therapeutics. July 2010 in press
• M Czejka, J Schueller, D Ettlinger, U Steinhauser, A Kiss, E Ostermann, A Farkouh:
  Clinical pharmacokinetics and metabolism of irinotecan when combined with the monoclonal antibody bevacizumab.
  In preparation 2010
• Czejka M, Schueller J , Kiss A, Koessner C, Terkola R, Farkouh A:
  Clinical pharmacokinetics and metabolism of irinotecan during intra-arterial chemotherapy.
  In preparation 2010

• M Czejka, B Gruenberger, A Kiss, A Farkouh, J Schueller:
  Clinical Pharma-cokinetics and metabolism of CPT-11 in patients with advanced colorectal cancer when combined with biweekly cetuximab (Erbitux®).
  Anticancer Res. 2010, in press
• M Czejka:
  Pharmazeutische Grundlagen in der klinischen Prüfung: Konzepte Pharmakokinetischer Untersuchungen.
  Onkologie 2008 (31) Suppl 2, 29-33
• K Hochegger, K Lhotta, G Mayer, M Czejka, W Hilbe:
  Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer.
  J Nephrol Dial Transplant. 2007 (22) 289-90
• D Ettlinger, M Mitterhauser, W Wadsak, E Ostermann, A Farkouh, J Schueller, M Czejka:
  In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.
  Anticancer Research 2006 (26) 1337 - 41
• A Furtlehner, J Schueller, I Jarisch, E Ostermann, M Czejka:
  Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Herceptin®).
  Eur J Drug Metab Pharmacokin, 2005. Vol. 30 (3), 145 -150
• M Czejka, E Ostermann, L Muric, D Heinz, J Schueller:
  Disposition of gemcitabine combined with trastuzumab in patients with advanced breast cancer (ABC).
  Onkologie (Karger), 2005 (28), 318 - 322
• M Czejka, J Schueller, K Hauer, E Ostermann:
  Pharmacokinetics and metabolism of CPT-11 combined with capecitabine in patients with advanced colorectal cancer.
  Anticancer Res, 2005 (25) 2985 - 2990
• M Czejka, J Schueller, H Schnait, B Springer, I Eder:
  Clinical pharmacokinetics and metabolism of paclitaxel after 3-hour infusion: comparison of two preparations.
  J Oncol Pharm Pract, 2003 (9) 127 - 136